Serum immunoglobulins in 28 adults with autoimmune sensorineural hearing loss: increased prevalence of subnormal immunoglobulin G1 and immunoglobulin G3

BMC Immunology

James C Barton²  J Clayborn Barton³  Dennis G Pappas¹  Luigi F Bertoli⁴ 

[1] Pappas Ear Clinic, Birmingham, AL, USA;Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA;Southern Iron Disorders Center, Birmingham, AL, USA;Brookwood Biomedical, Birmingham, AL, USA

关键词: IgG3;    IgG1;    IgG subclass deficiency (IgGSD);    IgG;    Common variable immunodeficiency (CVID);    Autoimmune sensorineural hearing loss;    For indexing;   

Others  :  1077690
DOI  :  10.1186/s12865-014-0043-2

 received in 2014-04-15, accepted in 2014-09-24,  发布年份 2014

【 摘 要 】

Background

Our informal observations suggested that some patients with acute sensorineural hearing loss (ASNHL) have subnormal serum immunoglobulin (Ig) levels. We evaluated 28 consecutive adults (18 men, 10 women) at ASNHL diagnosis using: antibodies to 68 kD protein, 30 kD protein, and type II collagen; and serum total IgG, IgG subclasses, total IgA, and IgM. Reference ranges for Ig levels were mean ± 2 SD. We compared prevalences of subnormal IgG subclasses to those in 275 healthy European adults in previous reports. We also reviewed charts of consecutive adult index patients with primary Ig deficiency (35 common variable immunodeficiency, 406 IgG subclass deficiency) to identify other patients with probable ASHNL.

Results

Mean age was 53 ± 10 (SD) y. Six patients (21.4%) had other autoimmunity manifestations. Antibodies to 68 kD protein, 30 kD protein, and type II collagen were detected in 21.4% (6/28), 21.1% (4/19) and 18.8% (3/16), respectively. Three patients (10.7%) had subnormal IgG1, six (21.4%) had subnormal IgG3, and four (14.3%) had subnormal IgG1 and IgG3. Some had subnormal IgG2, IgG4, IgA, and IgM (n = 1, 2, 3, and 1, respectively). Prevalences of subnormal IgG1 or IgG3 were greater in ASNHL patients (25.0% and 35.7%) than 275 controls (2.1% and 3.3%), respectively (p < 0.0001, each comparison). Relative risks of subnormal IgG1 and IgG3 in ASNHL were 11.5 [95% CI: 4.1, 31.7] and 10.9 [4.8, 25.6], respectively. Hearing improved after initial therapy in 17 patients (60.7%). Multiple regressions on Ig levels revealed no significant associations with other available variables. Logistic regressions on initial therapy response revealed a positive association with men (p = 0.0392) and a negative association with IgA (p = 0.0274). Our estimated prevalence of probable ASNHL in 35 patients with common variable immunodeficiency during a follow-up interval of 8 ± 4 y was 0% [95% CI: 0, 12.3]). Prevalence of probable ASNHL in 406 patients with IgG subclass deficiency during the same interval was 0.74% [0.19, 2.33].

Conclusions

Serum levels of IgG1 or IgG3 were subnormal in 46.4% of 28 patients with ASNHL. Among adults who present with primary Ig deficiency, some may have or later develop ASNHL.

【 授权许可】

   
2014 Bertoli et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]McCabe BF: Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979, 88:585-589.
• [2]Hughes GB, Barna BP, Kinney SE, Calabrese LH, Nalepa NJ: Clinical diagnosis of immune inner-ear disease. Laryngoscope 1988, 98:251-253.
• [3]Matsuoka AJ, Harris JP: Autoimmune inner ear disease: a retrospective review of forty-seven patients. Audiol Neurootol 2013, 18:228-239.
• [4]Gottschlich S, Billings PB, Keithley EM, Weisman MH, Harris JP: Assessment of serum antibodies in patients with rapidly progressive sensorineural hearing loss and Meniere’s disease. Laryngoscope 1995, 105:1347-1352.
• [5]Hirose K, Wener MH, Duckert LG: Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope 1999, 109:1749-1754.
• [6]Ianuale C, Cadoni G, De Feo E, Liberati L, Simo RK, Paludetti G, Ricciardi W, Boccia S: A systematic review and meta-analysis of the diagnostic accuracy of anti-heat shock protein 70 antibodies for the detection of autoimmune hearing loss. Otol Neurotol 2013, 34:214-219.
• [7]Tomasi JP, Lona A, Deggouj N, Gersdorff M: Autoimmune sensorineural hearing loss in young patients: an exploratory study. Laryngoscope 2001, 111:2050-2053.
• [8]Pham BN, Rudic M, Bouccara D, Sterkers O, Belmatoug N, Bebear JP, Couloigner V, Fraysse B, Gentine A, Ionescu E, Robier A, Sauvage JP, Truy E, Van Den AT, Ferrary E: Antibodies to myelin protein zero (P0) protein as markers of auto-immune inner ear diseases. Autoimmunity 2007, 40:202-207.
• [9]Yoo TJ, Du X, Kwon SS: Molecular mechanism of autoimmune hearing loss. Acta Otolaryngol Suppl 2002, 548:3-9.
• [10]Nair TS, Kozma KE, Hoefling NL, Kommareddi PK, Ueda Y, Gong TW, Lomax MI, Lansford CD, Telian SA, Satar B, Arts HA, El Kashlan HK, Berryhill WE, Raphael Y, Carey TE: Identification and characterization of choline transporter-like protein 2, an inner ear glycoprotein of 68 and 72 kDa that is the target of antibody-induced hearing loss. J Neurosci 2004, 24:1772-1779.
• [11]Kommareddi PK, Nair TS, Vallurupalli M, Telian SA, Arts HA, El Kashlan HK, Sataloff RT, Carey TE: Autoantibodies to recombinant human CTL2 in autoimmune hearing loss. Laryngoscope 2009, 119:924-932.
• [12]Traiffort E, O’Regan S, Ruat M: The choline transporter-like family SLC44: properties and roles in human diseases. Mol Aspects Med 2013, 34:646-654.
• [13]Baek MJ, Park HM, Johnson JM, Altuntas CZ, Jane-Wit D, Jaini R, Solares CA, Thomas DM, Ball EJ, Robertson NG, Morton CC, Hughes GB, Tuohy VK: Increased frequencies of cochlin-specific T cells in patients with autoimmune sensorineural hearing loss. J Immunol 2006, 177:4203-4210.
• [14]Zeitoun H, Beckman JG, Arts HA, Lansford CD, Lee DS, El Kashlan HK, Telian SA, Denny DE, Ramakrishnan A, Nair TS, Disher MJ, Sataloff RT, Fisher SG, Carey TE: Corticosteroid response and supporting cell antibody in autoimmune hearing loss. Arch Otolaryngol Head Neck Surg 2005, 131:665-672.
• [15]Rauch SD, Halpin CF, Antonelli PJ, Babu S, Carey JP, Gantz BJ, Goebel JA, Hammerschlag PE, Harris JP, Isaacson B, Lee D, Linstrom CJ, Parnes LS, Shi H, Slattery WH, Telian SA, Vrabec JT, Reda DJ: Oral vs intratympanic corticosteroid therapy for idiopathic sudden sensorineural hearing loss: a randomized trial. JAMA 2011, 305:2071-2079.
• [16]Harris JP, Weisman MH, Derebery JM, Espeland MA, Gantz BJ, Gulya AJ, Hammerschlag PE, Hannley M, Hughes GB, Moscicki R, Nelson RA, Niparko JK, Rauch SD, Telian SA, Brookhouser PE: Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial. JAMA 2003, 290:1875-1883.
• [17]Alexander TH, Harris JP: Incidence of sudden sensorineural hearing loss. Otol Neurotol 2013, 34:1586-1589.
• [18]Barton JC, Bertoli LF, Acton RT: HLA-A and -B alleles and haplotypes in 240 index patients with common variable immunodeficiency and selective IgG subclass deficiency in central Alabama. BMC Med Genet 2003, 4:3. BioMed Central Full Text
• [19]Sarmiento E, Mora R, Rodriguez-Mahou M, Rodriguez-Molina J, Fernandez-Cruz E, Carbone J: Autoimmune disease in primary antibody deficiencies. Allergol Immunopathol (Madr) 2005, 33:69-73.
• [20]Agarwal S, Cunningham-Rundles C: Autoimmunity in common variable immunodeficiency. Curr Allergy Asthma Rep 2009, 9:347-352.
• [21]O’Keeffe S, Gzel A, Drury R, Cullina M, Greally J, Finnegan P: Immunoglobulin G subclasses and spirometry in patients with chronic obstructive pulmonary disease. Eur Respir J 1991, 4:932-936.
• [22]Hill SL, Mitchell JL, Burnett D, Stockley RA: IgG subclasses in the serum and sputum from patients with bronchiectasis. Thorax 1998, 53:463-468.
• [23]Schauer U, Stemberg F, Rieger CH, Borte M, Schubert S, Riedel F, Herz U, Renz H, Wick M, Carr-Smith HD, Bradwell AR, Herzog W: IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. Clin Chem 2003, 49:1924-1929.
• [24]Conley ME, Notarangelo LD, Etzioni A: Diagnostic criteria for primary immunodeficiencies: representing PAGID (Pan-American Group for Immunodeficiency) and ESID (European Society for Immunodeficiencies). Clin Immunol 1999, 93:190-197.
• [25]Aghamohammadi A, Louganis V, Plebani A, Miyawaki T, Durandy A, Hammarström L: Predominantly antibody deficiencies. In Immunodeficiency Diseases: Definition, Diagnosis, and Management. Edited by Rezaei N, Aghamohammadi A, Notarangelo D. Springer, Berlin; 2000:97-130.
• [26]Shulman G, Gilich GC, Andrew MJ: Serum immunoglobulins G, A and M in white and black adults on the Witwatersrand. S Afr Med J 1975, 49:1160-1164.
• [27]Lewis M, Miyashiro M, Huton J, Miller L, Sperber K: Immunoglobulin and IgG subclass levels in the African American and Hispanic populations of east Harlem. Mt Sinai J Med 1998, 65:139-145.
• [28]Cunningham-Rundles C, Bodian C: Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999, 92:34-48.
• [29]Gardner G, Robertson JH: Hearing preservation in unilateral acoustic neuroma surgery. Ann Otol Rhinol Laryngol 1988, 97:55-66.
• [30]Schroeder HW Jr, Zhu ZB, March RE, Campbell RD, Berney SM, Nedospasov SA, Turetskaya RL, Atkinson TP, Go RC, Cooper MD, Volanakis JE: Susceptibility locus for IgA deficiency and common variable immunodeficiency in the HLA-DR3, −B8, −A1 haplotypes. Mol Med 1998, 4:72-86.
• [31]Barna BP, Hughes GB: Autoimmunity and otologic disease: clinical and experimental aspects. Clin Lab Med 1988, 8:385-398.
• [32]Srikumar S, Deepak MK, Basu S, Kumar BN: Sensorineural hearing loss associated with psoriatic arthritis. J Laryngol Otol 2004, 118:909-911.
• [33]Bowman CA, Nelson RA: Human leukocytic antigens in autoimmune sensorineural hearing loss. Laryngoscope 1987, 97:7-9.
• [34]Cao MY, Thonnard J, Deggouj N, Gersdorff M, Philippe M, Osselaer JC, Tomasi JP: HLA class II-associated genetic susceptibility in idiopathic progressive sensorineural hearing loss. Ann Otol Rhinol Laryngol 1996, 105:628-633.
• [35]Psillas G, Daniilidis M, Gerofotis A, Veros K, Vasilaki A, Vital I, Markou K: Sudden bilateral sensorineural hearing loss associated with HLA A1-B8-DR3 haplotype. Case Rep Otolaryngol 2013, 2013:590157.
• [36]Dechavanne C, Guillonneau F, Chiappetta G, Sago L, Levy P, Salnot V, Guitard E, Ehrenmann F, Broussard C, Chafey P, Le Port A, Vinh J, Mayeux P, Dugoujon JM, Lefranc MP, Migot-Nabias F: Mass spectrometry detection of G3m and IGHG3 alleles and follow-up of differential mother and neonate IgG3. PLoS One 2012, 7:e46097.
• [37]Morell A, Skvaril F, Steinberg AG, van Loghem E, Terry WD: Correlations between the concentrations of the four sub-classes of IgG and Gm Allotypes in normal human sera. J Immunol 1972, 108:195-206.
• [38]Grubb R, Hallberg T, Hammarstrom L, Oxelius VA, Smith CI, Soderstrom R, Soderstrom T: Correlation between deficiency of immunoglobulin subclass G3 and Gm allotype. Acta Pathol Microbiol Immunol Scand C 1986, 94:187-191.
• [39]Oxelius VA, Ochs HD, Hammarstrom L: Restricted immunoglobulin constant heavy G chain genes in primary immunodeficiencies. Clin Immunol 2008, 128:190-198.
• [40]Bonaguri C, Orsoni JG, Zavota L, Monica C, Russo A, Pellistri I, Rubino P, Giovannelli L, Manzotti F, Piazza F: Anti-68 kDa antibodies in autoimmune sensorineural hearing loss: are these autoantibodies really a diagnostic tool? Autoimmunity 2007, 40:73-78.